Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas

Table 5 Results from followed patients with non-operated main-duct or mixed intraductal papillary mucinous neoplasm of the pancreas

Ref.	Patients, n	Malignant progression	Time to progression in month, mean (range)	Predictors of malignant progression
Uehara et al[17], 2010	20	40%	(20-35)	None1
Takuma et al[18], 2011	20	20%	32 (17-65)	Dilatation of the MPD > 10 mm
Ogura et al[16], 2013	20	40%	30 (18-46)	Dilatation of the MPD > 15 mm; diffuse lesions
Roch et al[36], 2014	70	13%	42 (12-108)	Diffuse dilatation of the MPD2
Present study	50	36%	33 (8-141)	Dilatation of the MPD > 10 mm

¹Intraductal papillary mucinous neoplasm with lower likelihood of malignancy at baseline;

²Also included an increase in serum carbohydrate antigen 19-9 and alkaline phosphatase levels, absence of extra pancreatic cyst. MPD: Main pancreatic duct.